BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 26665661)

  • 1. [Generic and biosimilar drug substitution: a panacea?].
    Daly MJ; Guignard B; Nendaz M
    Rev Med Suisse; 2015 Oct; 11(490):1909-12, 1914. PubMed ID: 26665661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited distribution networks stifle competition in the generic and biosimilar drug industries.
    Karas L; Shermock KM; Proctor C; Socal M; Anderson GF
    Am J Manag Care; 2018 Apr; 24(4):e122-e127. PubMed ID: 29668215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars in the Caribbean--key considerations.
    Cox SD
    West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prescription of generic drugs to privately insured persons].
    Wild F
    Versicherungsmedizin; 2012 Dec; 64(4):190-2. PubMed ID: 23236709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
    Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A "Method of Use" to Prevent Generic and Biosimilar Market Entry.
    Tu SS; Sarpatwari A
    N Engl J Med; 2023 Feb; 388(6):483-485. PubMed ID: 36734878
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilars: How Can Payers Get Long-Term Savings?
    Mestre-Ferrandiz J; Towse A; Berdud M
    Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First biosimilar drug set to enter US market.
    Ledford H
    Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512
    [No Abstract]   [Full Text] [Related]  

  • 9. Limited options to manage specialty drug spending.
    Tu HT; Samuel DR
    Res Brief; 2012 Apr; (22):1-13. PubMed ID: 23155549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Is the Future of Generics in Transplantation?
    van Gelder T
    Transplantation; 2015 Nov; 99(11):2269-73. PubMed ID: 26050017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief history of generic substitution in the USA.
    Sullivan CG
    Pharm Pat Anal; 2012 Mar; 1(1):9-11. PubMed ID: 24236706
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
    Bennett CL; Sartor OA; Armitage JO; Kantarjian H
    Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
    [No Abstract]   [Full Text] [Related]  

  • 13. Active Surveillance of Follow-on Biologics: A Prescription for Uptake.
    Sarpatwari A; Gagne JJ; Levidow NL; Kesselheim AS
    Drug Saf; 2017 Feb; 40(2):105-108. PubMed ID: 27838823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

  • 16. Incentives for market penetration of biosimilars in Belgium and in five European countries.
    Swartenbroekx N; Farfan-Portet ; EspĂ­n J; Gerkens S
    J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
    Hernandez I; Gellad WF
    J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generics and Biosimilars: Barriers and Opportunities.
    Scheckel CJ; Rajkumar SV
    Mayo Clin Proc; 2021 Dec; 96(12):2947-2957. PubMed ID: 34728057
    [No Abstract]   [Full Text] [Related]  

  • 20. How drug life-cycle management patent strategies may impact formulary management.
    Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
    Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.